FY2024 Earnings Forecast for Trevena Issued By HC Wainwright

Trevena, Inc. (NASDAQ:TRVN) – Equities researchers at HC Wainwright raised their FY2024 earnings estimates for shares of Trevena in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings per share of ($23.04) for the year, up from their prior estimate of ($32.25). HC Wainwright currently has a “Neutral” rating and a $5.00 target price on the stock. The consensus estimate for Trevena’s current full-year earnings is ($23.04) per share. HC Wainwright also issued estimates for Trevena’s Q4 2024 earnings at ($2.50) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.31) EPS.

Separately, StockNews.com started coverage on Trevena in a report on Monday, November 11th. They issued a “sell” rating on the stock.

Trevena Trading Down 0.6 %

NASDAQ TRVN opened at $1.68 on Monday. The stock has a market cap of $1.45 million, a P/E ratio of -0.04 and a beta of 1.08. The company has a fifty day simple moving average of $3.05 and a two-hundred day simple moving average of $5.61. Trevena has a 12-month low of $1.13 and a 12-month high of $19.23.

Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million during the quarter.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.